Lantern Pharma(US:LTRN)2025-05-15 13:08Clinical Development - LP-184 Phase 1a clinical trial is expected to be completed by the end of June 2025 with 62-65 patients enrolled across a range of solid tumors[9] - Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer is anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort[9] - Independent preclinical confirmation of LP-184 hypersensitivity in rare pediatric brain tumors, such as ATRT, by collaborators at Johns Hopkins supports a planned pediatric trial in CNS tumors[12] RADR® AI Platform - The company strengthened its AI intellectual property portfolio with PCT publication of a proprietary blood-brain barrier penetration prediction patent application[9] - The RADR® platform was expanded with an innovative AI-powered module to improve the precision, cost, and timeline of antibody-drug conjugate (ADC) development[9] - The company is planning commercial availability and launch of select RADR® AI modules for the scientific and research community to foster collaborative, open-source innovation in cancer drug development[12] Financial Status - As of March 31, 2025, the company maintained disciplined capital management, with approximately $19.7 million in cash, cash equivalents, and marketable securities, providing an expected operating runway through at least May 15, 2026[12] - Total operating expenses for the three months ended March 31, 2025 were $4,774,032, compared to $5,732,001 for the same period in 2024[14] - Net loss for the three months ended March 31, 2025 was $4,536,783, or $0.42 per common share, compared to a net loss of $5,440,810, or $0.51 per common share, for the same period in 2024[14]